

Examiner Everett White
U.S. Application Serial No. 09/700,057
Page 6

~~acts as an osmotic agent to maintain a volume of the aqueous formulation in the body cavity serving to separate tissues which otherwise may adhere to each other.~~

40. (Currently Amended) A prevention kit comprising an aqueous formulation of polysaccharide dextrin in an amount effective to reduce said adhesions, wherein the dextrin is unsubstituted and contains more than 15% of polymers with a degree of polymerisation (DP) greater than 12 and acts as an osmotic agent to maintain a volume of the aqueous formulation in the body cavity serving to separate tissues which otherwise may adhere to each other, and wherein the prevention kit is useful for surgical use for reducing the prevention of adhesions in a body cavity of animals or humans.

41. (Currently Amended) The [[A]] kit according to Claim 40, wherein the kit is biocompatible.

42. (Currently Amended) The [[A]] kit according to Claim 40, wherein the kit is bioresorbable.

43. (Currently Amended) The [[A]] kit according to Claim 40, wherein the kit is non-toxic.

Remarks

Claims 1, 2, 4-12, 14-18, 21-24, 26-35 and 39-43 are pending in the present application.

I. Claim Rejections Under 35 U.S.C. § 112, Second Paragraph

Claims 1-12, 14-18, 21, 22 and 39 stand rejected under 35 U.S.C. § 112, second paragraph, as being indefinite. We propose amending claim 1 to delete the recitations directed to "substituted" dextrin.

Examiner Everett White
U.S. Application Serial No. 09/700,057
Page 7

II. Claim Rejections Under 35 U.S.C. § 112, First Paragraph

Claims 1-35, 37 and 39-43 stand rejected under 35 U.S.C. § 112, first paragraph, as lacking enablement. We proposed amending the claims to delete the term "preventing."

III. Claim Rejections Under 35 U.S.C. § 103

Claims 22 and 40-43 stand rejected under 35 U.S.C. § 103 as being obvious in view of U.S. Patent No. 5,258,175 to Davies. We proposed amending claim 22 to delete the recitation directed to the dextrin "sulphate." We also propose amending claim 40 to incorporate the recitations of claim 1 to further clarify the dextrin composition in the kits of the present invention.

Claims 1, 2, 4-12, 14-18, 21, 22, 39 and 40-43 stand rejected under 35 U.S.C. § 103 as being obvious over U.S. Patent No. 5,587,175 to Viegas et al. in view of Davies. As noted above, we propose amending claim 1 to delete the recitations directed to "substituted" dextrin.

Claims 23, 24 and 26-35 stand rejected under 35 U.S.C. § 103 as being obvious over Viegas in view of U.S. Patent No. 4,886,789 to Milner. We propose amending claim 23 to include the recitations of amended claim 1 which is not subject to an obviousness rejection over Viegas and Milner.

Any questions that the Examiner may have should be directed to Shawna Cannon Lemon, Ph.D., Esq., who may be reached at (919) 854-1400.

Confidentiality Note

The information contained in this facsimile message is legally privileged and confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby prohibited. If you have received this telecopy in error, please immediately notify us by telephone and return the original message to us at the address above via the United States Postal Service. THANK YOU.